The bill aims to improve access to insulin by implementing a cap on the out-of-pocket costs for individuals requiring insulin. Specifically, it mandates that individuals cannot be required to pay more than $100 for a 30-day supply of insulin, regardless of the type or amount prescribed. This provision is added to multiple sections of the General Laws, including Chapter 32A, Chapter 118E, and various insurance-related chapters (175, 176A, 176B, and 176G), ensuring that both public and private insurers adhere to this cap.

Additionally, the bill establishes requirements for pharmaceutical and medical device manufacturers regarding their insulin patient assistance programs. It mandates that these companies provide a no-cost, one-time 30-day supply of insulin for individuals who urgently need it and are at risk of rationing. The bill outlines eligibility criteria for these programs, including income limits and lack of private prescription drug coverage. Companies that fail to comply with these provisions face significant fines, reinforcing the importance of adherence to the new regulations.

Statutes affected:
Bill Text: 118E-10C, 175-47N, 176A-8P, 176B-4S, 176G-4H